Biomedical Occupation or Discipline
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.
Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership
Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions
Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.
WHO Negotiations Extended for Global Pandemic Agreement
World Health Organization (WHO), pandemic accord, international agreement, global health, deadline, negotiations, public health emergency, disease outbreaks.
Blackstone Invests $300M in Uniquity Bio to Unleash Merck Drug’s Inflammation & Immunology Potential
Blackstone, Uniquity Bio, Merck, Inflammation & Immunology, Investment, Drug Development, Biotechnology
BioMarin Downsizes Workforce Amidst Strategic R&D Shift
BioMarin, job cuts, R&D refocus, biotechnology, strategic shift, workforce reduction
Sands Capital Successfully Raises $555 Million for Third Life Sciences Venture Fund
Sands Capital, life sciences, venture fund, fundraising, healthcare investments, biotechnology, medical technology, pharmaceuticals, healthcare innovation.
Revolutionizing Pharmaceuticals: Nabla Bio Secures $26M for AI-Powered Protein Design
Nabla Bio, generative AI, protein design, funding, pharmaceutical partners, biotechnology, drug discovery.
AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership
AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.
Ajax Pharmaceuticals Secures $95 Million for JAK Inhibitor Drug Development
Ajax Pharmaceuticals, JAK inhibitors, drug development, funding, investment, inflammatory diseases, autoimmune disorders, cancer.